Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
2569 | 2133 | 37.8 | 71% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ADHERENCE | Author keyword | 78 | 10% | 34% | 724 |
2 | ANTIRETROVIRAL ADHERENCE | Author keyword | 27 | 71% | 1% | 22 |
3 | ART ADHERENCE | Author keyword | 24 | 63% | 1% | 24 |
4 | AIDS PATIENT CARE AND STDS | Journal | 22 | 12% | 8% | 178 |
5 | EPIDEMIOL PREVENT INTERVENT | Address | 16 | 41% | 1% | 30 |
6 | ARV ADHERENCE | Author keyword | 11 | 100% | 0% | 6 |
7 | DIRECTLY ADMINISTERED ANTIRETROVIRAL THERAPY | Author keyword | 9 | 83% | 0% | 5 |
8 | PROJECT MOTIV8 | Address | 8 | 100% | 0% | 5 |
9 | DIRECTLY OBSERVED THERAPY | Author keyword | 7 | 21% | 1% | 28 |
10 | REGIMEN COMPLEXITY | Author keyword | 6 | 80% | 0% | 4 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SELF REPORTED ADHERENCE | 280 | 73% | 10% | 214 |
2 | REPORTED ADHERENCE | 89 | 62% | 4% | 91 |
3 | MEDICATION ADHERENCE | 75 | 16% | 20% | 424 |
4 | LESS THAN 95 PERCENT | 53 | 79% | 2% | 34 |
5 | HAART | 49 | 20% | 10% | 222 |
6 | THERAPY ADHERENCE | 47 | 68% | 2% | 41 |
7 | ART ADHERENCE | 41 | 90% | 1% | 18 |
8 | INHIBITOR THERAPY | 40 | 43% | 3% | 71 |
9 | ANTIRETROVIRAL THERAPY ADHERENCE | 34 | 53% | 2% | 45 |
10 | VIRAL SUPPRESSION | 23 | 25% | 4% | 81 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | AIDS PATIENT CARE AND STDS | 22 | 12% | 8% | 178 |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Adherence to antiretroviral therapy in sub-Saharan Africa and North America - A meta-analysis | 2006 | 360 | 58 | 71% |
Association between antiretroviral therapy adherence and employment status: systematic review and meta-analysis | 2015 | 1 | 51 | 73% |
Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management | 2006 | 225 | 83 | 84% |
Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators | 2006 | 232 | 55 | 80% |
Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward | 2010 | 144 | 75 | 47% |
A Proposal for Quality Standards for Measuring Medication Adherence in Research | 2013 | 20 | 64 | 77% |
Identification of Evidence-Based Interventions for Promoting HIV Medication Adherence: Findings from a Systematic Review of US-Based Studies, 1996-2011 | 2014 | 6 | 84 | 81% |
Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies | 2011 | 64 | 74 | 62% |
Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review | 2008 | 90 | 61 | 80% |
Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis | 2014 | 8 | 61 | 43% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | EPIDEMIOL PREVENT INTERVENT | 16 | 41% | 1.4% | 30 |
2 | PROJECT MOTIV8 | 8 | 100% | 0.2% | 5 |
3 | PHARMACEUT OUTCOMES GRP | 6 | 100% | 0.2% | 4 |
4 | PERUVIAN HIV PROGRAM | 4 | 67% | 0.2% | 4 |
5 | ADM HIV AIDS CONTROL | 4 | 75% | 0.1% | 3 |
6 | LIVING HIV PROGRAM | 4 | 75% | 0.1% | 3 |
7 | PHARM PHARM ADM PRACTICE | 3 | 100% | 0.1% | 3 |
8 | GAY MENS HLTH | 3 | 50% | 0.2% | 4 |
9 | HLTH HIV INTERVENT PREVENT | 2 | 33% | 0.3% | 6 |
10 | ABORAT PROGRAMME AIDS S AFRICA | 2 | 67% | 0.1% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000185575 | LOSS TO FOLLOW UP//KNOWLEDGE TRANSLAT UNIT//HLTH ECON EPIDEMIOL OFF |
2 | 0.0000184570 | ROYAL FREE HIV MED//CD4 CELL COUNT//X BICHAT MED |
3 | 0.0000160728 | RETENTION IN CARE//ENGAGEMENT IN CARE//HIV CARE CONTINUUM |
4 | 0.0000143985 | MOS HIV//WHOQOL HIV BREF//WHOQOL HIV |
5 | 0.0000139203 | HLTH INEQUAL PROGRAM//AIDS CLIN SERV//HLTH INEQUALIT PROGRAM |
6 | 0.0000110806 | MHEALTH//MALARIA PUBL HLTH CLUSTER//COMMCARE |
7 | 0.0000092635 | STIGMA//HIV RELATED STIGMA//HIV DISCLOSURE |
8 | 0.0000085574 | MEDICATION ADHERENCE//PATIENT COMPLIANCE//MORISKY SCALE |
9 | 0.0000076885 | PRE EXPOSURE PROPHYLAXIS//POST EXPOSURE PROPHYLAXIS//TREATMENT AS PREVENTION |
10 | 0.0000072562 | HIV AFFECTED CHILDREN//PERINATALLY ACQUIRED HIV//MATERNAL HIV |